Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

August PDUFA Preview

8/1/2019

 
There are seven investigational drugs with PDUFA Dates in August 2019.
  1. ​Pexidartinib from Daiichi Sankyo/Plexxikon with an August 3, 2019 PDUFA Date is a CSF-1R inhibitor administered orally to treat giant cell tumors of the tendon sheath. Pexidartinib has Orphan and Breakthrough Therapy priority designations. 
  2. Bioproject Pharma’s Pitolisant has an August 12, 2019 PDUFA Date and is a H3 receptor antagonist administered orally for treating Narcolepsy. Pitolisant has Breakthrough and Fast Track priority designations.
  3. Entrectinib from Roche, PDUFA Date of August 18, 2019, is an oral Tyrosine kinase inhibitor for the treatment of advanced or metastatic solid tumors that harbor NTRK1/2/3 or ROS1 gene activating fusions. Roche is seeking approval based on an integrated analysis from four Phase I and II trials that included data from 53 people with ROS1-activating gene fusions and 54 people with locally advanced or metastatic NTRK fusion-positive solid tumors. If approved, entrectinib would compete with larotrectinib to treat NTRK-fusion positive solid tumors and critzotinib to treat ROS1-mutated non-small cell lung cancer. The drug has a Breakthrough Therapy priority designation.
  4. Sarepta Therapeutics’ golodirsen’s PDUFA Date is set for August 19, 2019. The drug is an Exon 53 skipping Intravenous infusion targeting Duchenne muscular dystrophy. A review by ICER of treatments for Duchenne’s found limited data that a slight increase in levels of dystrophin with eteplirsen and golodirsen provides a clinically significant effect. ICER concluded that if golodirsen is priced like eteplirsen, it would not meet cost benefit standards. At the current price, if either drug were able to restore perfect health in DMD patients for an additional 40 years of life, the drugs would far exceed cost-effectiveness thresholds of $100,000 and $150,000 per Quality-Adjusted Life Year (QALY) gained or $100,000 and $150,000 per Life Year Gained (LYG).
  5. Lefamulin from Nabriva has an August 19, 2019 PDUFA Date. It’s a pleuromutilin antibiotic administered orally or by intravenous bolus to treat community-acquired pneumonia. The drug has Fast Track and Qualified Infectious Disease Product (QIDP) priority designations. 
  6. AbbVie’s upadacitinib, with a PDUFA Date of August 19, 2019, is an oral JAK Inhibitor for the treatment of Rheumatoid Arthritis and Crohn's disease. The product has a Breakthrough Therapy priority designation.
  7. Istradefylline from Kyowa Hakko Kirin has a PDUFA Date of August 27, 2019 and is an A2A antagonist administered orally for patients on levodopa therapy with Parkinson's Disease wearing-off phenomenon. Istradefylline is approved in Japan as adjunctive therapy for the treatment of Parkinson's Disease. The FDA rejected Istradefylline in February 2008 due to efficacy concerns. The FDA accepted the NDA for istradefylline in April 2019 and set the August PDUFA date at that time. The drug has no priority designations. 

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.